Xilio Therapeutics, Inc. Retained Earnings
Xilio Therapeutics, Inc. (XLO) had Retained Earnings of -$434.69 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-12
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$434.69M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$428.32M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$418.79M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$429.15M.
| Period end | Retained Earnings (Accumulated Deficit) |
|---|---|
| 2026-06-30 | -$434.69M 10-Q · filed 2026-08-12 |
| 2026-03-31 | -$428.32M 10-Q · filed 2026-05-12 |
| 2025-12-31 | -$418.79M 10-Q · filed 2026-08-12 |
| 2025-09-30 | -$429.15M 10-Q · filed 2025-11-13 |
| 2025-06-30 | -$412.86M 10-Q · filed 2025-08-14 |
| 2025-03-31 | -$397.02M 10-Q · filed 2025-05-08 |
| 2024-12-31 | -$383.75M 10-K · filed 2026-03-23 |
| 2024-09-30 | -$370.66M 10-Q · filed 2024-11-07 |
| 2024-06-30 | -$356.64M 10-Q · filed 2024-08-08 |
| 2024-03-31 | -$342.71M 10-Q · filed 2024-05-14 |
| 2023-12-31 | -$325.51M 10-K · filed 2025-03-11 |
| 2023-09-30 | -$307.86M 10-Q · filed 2023-11-09 |
| 2023-06-30 | -$291.11M 10-Q · filed 2023-08-14 |
| 2023-03-31 | -$271.75M 10-Q · filed 2023-05-09 |
| 2022-12-31 | -$249.11M 10-K · filed 2024-04-01 |
| 2022-09-30 | -$226.64M 10-Q · filed 2022-11-09 |
| 2022-06-30 | -$206.85M 10-Q · filed 2022-08-09 |
| 2022-03-31 | -$182.24M 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$160.89M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$141.19M 10-Q · filed 2021-12-02 |
| 2020-12-31 | -$85.09M 10-K · filed 2022-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Serina Therapeutics, Inc. (SER) | United States | $0.054B | -2.35 |
| Clene Inc. (CLNN) | United States | $0.054B | -1.99 |
| HERON THERAPEUTICS, INC. /DE/ (HRTX) | United States | $0.055B | -2.38 |
| Elicio Therapeutics, Inc. (ELTX) | United States | $0.049B | |
| Lite Strategy, Inc. (LITS) | United States | $0.049B | |
| Dogwood Therapeutics, Inc. (DWTX) | United States | $0.049B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 |